Slide 1: BlinkLab to Present at Spark+ Aussie Equities Day Singapore
ASX:BB1 ASX Announcement 9 October 2026 For personal use only BlinkLab to Present at Spark+ Aussie Equities Day Singapore BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), a digital healthcare company developing AI-powered diagnostic tools, is pleased to announce that Chairman Mr Brian Leedm
Slide 2: An AI-Powered Smartphone Platform for Neurometric Testing
rsonal use only E A R L I E R A N D M O R E A C C U R AT E D I A G N O S I S O F A U T I S M A N D A D H D AN AI-POWERED SMARTPHONE P L AT F O R M F O R N E U R O M E T R I C T E S T I N G C O R P O R AT E P R E S E N TAT I O N · A S X : B B 1 · O C T O B E R 2 0 2 6
Slide 3: Disclaimer
rsonal use only Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be all incl
Slide 4: Princeton University spin out: founders and management
Neuroscience · Artificial Intelligence · Mobile technology WE ARE A PRINCETON UNIVERSITY SPIN OUT · FOUNDED IN AUGUST 2021 · IPO IN APRIL 2024 rsonal use only Henk-Jan Boele, MD PhD Brian Leedman, MBA Anton Uvarov, PhD Raphael Bernier, PhD Samuel S.-H. Wang, PhD Peter Boele, MA Co-founder Non-Execut
Slide 5: Share price growth tracking clinical milestones
Share Price Growth Tracking Clinical Milestones F U L L B O A R D PA R T I C I PAT E D I N A L L C A P I TA L R A I S E S · F U L LY F U N D E D T O R E A C H C O M M E R C I A L S TA G E Nov 2024 Oct 2025 Mar 2026 Aug 2026 Shares on Issue rsonal use only Case-control autism results Autism pre-FDA p
Slide 6: Sensorimotor biomarkers widely studied but clinical adoption limited
Sensorimotor biomarkers have been widely studied in neuroscience BUT CLINICAL ADOPTION HAS BEEN LIMITED BY TECHNICAL COMPLEXITY Objective measurements of brain circuit function rsonal use only Over 9,000 peer-reviewed studies across a wide range Examples of technically-complex, laboratory- of neurop
Slide 7: The BlinkLab Solution: Smartphone-based sensorimotor assessments
The BlinkLab Solution: Smartphone-based sensorimotor assessments W O R L D F I R S T · I N V E N T E D , PAT E N T E D A N D P U B L I S H E D B Y B L I N K L A B F O U N D E R S rsonal use only Minuscule facial reflexes, elicited by our app, Evokes Facial Reflexes generate a digital biomarker for a
Slide 8: BlinkLab: How it works
BlinkLab: How it works REMOTE · CLINICAL GRADE · SCALABLE · ACCESSIBLE 1 2 3 rsonal use only Simple at-home set-up Short smartphone assessment Automated facial analysis Smartphone + headphones 10–15 minutes Selfie camera captures facial landmarks AI Algorithmic analysis of evoked neurometric respons
Slide 9: Our first product: BlinkLab Dx
Our first product: BlinkLab Dx 1 D I A G N O S T I C A I D F O R A U T I S M A S S E S S M E N T · F D A 5 1 0 ( K ) R E G U L AT O R Y P R O G R A M O N G O I N G rsonal use only Early Clinical Regulatory Pilot Study Pivotal Study FDA 510(k) FDA Commercial Work1 Preparation2,3 Program4 Program5 Sub
Slide 10: The growing need for scalable autism assessment
The growing need for scalable autism assessment R I S I N G G L O B A L P R E V A L E N C E · H I G H C O S T S · L I M I T E D C L I N I C A L C A PA C I T Y · L O N G WA I T L I S T Prevalence in children has grown to up to 3% in the US 1-3 Autism prevalence increases globally 4,5 rsonal use only
Slide 11: Autism diagnosis still lacks an objective medical test
Autism diagnosis still lacks an objective medical test C U R R E N T LY N O B I O M A R K E R , S U C H A S A B L O O D T E S T O R B R A I N S C A N , U S E D I N C L I N I C A L P R A C T I C E . rsonal use only Diagnosis relies on behavioral assessments based on DSM-5 Over 100 autism questionnair
Slide 12: Early diagnosis and intervention reduces long-term support needs and costs
Consensus: Early diagnosis and intervention helps children to develop crucial skills and reduces long-term support needs and costs rsonal use only Ø Early detection and diagnosis is crucial 1-5 The American Academy of Pediatrics recommends that all children must be screened for autism at ages 18 and
Slide 13: BlinkLab could help reduce the long-term cost of autism care
BlinkLab is not only a diagnostic technology; it could become an economic intervention that helps reduce the long-term cost of autism care The Present: NDIS Autism Costs: A$9.9B The Future: Today’s diagnosed children become the wave of tomorrow’s adult cost rsonal use only In 2025 autism accounted f
Slide 14: US autism assessments can cost US$1,200–$6,000+
US autism assessments can cost US$1,200–$6,000+ T R A D I T I O N A L D I A G N O S I S R E Q U I R E S M U LT I P L E S P E C I A L I S T S A N D E X T E N S I V E R E P O R T I N G T I M E rsonal use only Average self-pay cost by evaluation tier WITH COMMERCIAL INSURANCE Indicative US pricing befo
Slide 15: US Pilot Study Confirms High Diagnostic Accuracy and FDA Trial Readiness
US Pilot Study Confirms High Diagnostic Accuracy and FDA Trial Readiness BLINKLAB DX1 U.S. PILOT STUDY IN AUTISM · UNBLINDED 17 OCTOBER 2025 rsonal use only 84% SENSITIVITY 85% SPECIFICITY 485 CHILDREN ENROLLED, AGED 2–11 FDA endorsed the pivotal 510(k) design Tested in a real-world clinical populat
Slide 16: Why 100% sensitivity and 100% specificity is impossible
Why 100% sensitivity and 100% specificity is impossible PERFORMANCE CEILING IS 85-90% DUE TO DIAGNOSTIC AMBIGUITY AND AUTISM HETEROGENEITY rsonal use only 1st Evaluation Re-evaluation Diagnostic Stability Few years later... Autism clinical diagnostic stability is estimated around 80-90% stability. ¹
Slide 17: BlinkLab Commenced Pivotal Validation Program
BlinkLab Commenced Pivotal Validation Program F D A 5 1 0 ( K ) S U B M I S S I O N · F I R S T PA R T I C PA N T E N R O L L E D I N M A R C H 2 0 2 6 · S U B M I S S I O N E A R LY 2 0 2 7 rsonal use only Ten Leading US Autism Centers will Participate in the 510(k) Pivotal Study Prospective, multi
Slide 18: Dx1 is prescribed when developmental concerns warrant autism assessment
Dx1 is prescribed when developmental concerns warrant autism assessment A C L I N I C I A N - P R E S C R I B E D D I A G N O S T I C A I D · N O T A S TA N D - A L O N E T E S T rsonal use only Potential prescription triggers Concerns do not need to be autism-specific 1 Healthcare provider observat
Slide 19: We follow a conventional revenue model for medical devices
We follow a conventional revenue model for medical devices B2B PRESCRIPTION SaMD (SOFTWARE as MEDICAL DEVICE) · PAY PER ASSESSMENT rsonal use only What a clinic pays How we sell BlinkLab Dx1 BlinkLab Dx1 TBD Prescription device, sold to providers Not a consumer app and not direct to consumer. The pr
Slide 20: US commercialization strategy following FDA clearance
US commercialization strategy following FDA clearance S P E C I A L I S T- F I R S T L A U N C H · S C R E E N I N G A S A S E P A R A T E L A B E L E X P A N S I O N 2027 2028 2029 2030 2031+ rsonal use only COMMERCIAL ADOPTION INITIAL DIAGNOSTIC AID Launch readiness Late-2027 paid lighthouse launc
Slide 21: KOL engagement has been the strategy from day one
KOL engagement has been the strategy from day one KEY OPINION LEADERS · WE HAVE BEEN IN THIS FIELD FOR DECADES · WE’RE NOT SELLING INTO IT rsonal use only May 2024 Turning Pointe Autism Foundation, USA First US partnership after IPO. Jul 2024 Mental Care Group, Netherlands The Dx2 ADHD model. Nov 20
Slide 22: Our second product: BlinkLab Dx2
Our second product: BlinkLab Dx 2 DIAGNOSTIC AID FOR ADHD ASSESSMENT · SAME SMARTPHONE TECH AS DX1 · DIFFERENT USE CASE rsonal use only Early Clinical Regulatory Pilot Study Pivotal Study FDA FDA Commercial Work1 Preparation2 Program Program Submission Clearance Launch Regulatory Pipeline for BlinkL
Slide 23: The unmet need in ADHD is diagnostic
The unmet need in ADHD is diagnostic 7 MI L L I O N U S C H I L D R E N · 5 6 % O F A D U L T S D I A G N O S E D A F T E R 1 8 · N O O B J E C T I V E T E S T United States: prevalence keeps climbing 1-3 Australia: an 11-fold increase in ADHD medication prescribed 4-7 rsonal use only 11.0% 11.4% 22
Slide 24: ADHD assessment is costly and already shifting online
ADHD assessment is costly and already shifting online U S E V A L U AT I O N S C A N C O S T U S $ 2 0 0 – $ 5 , 0 0 0 + ; T E L E H E A LT H I S A L R E A D Y E M B E D D E D I N A D U LT A D H D C A R E rsonal use only ADHD CARE IS ALREADY DIGITAL Average cost by evaluation tier Indicative US pric
Slide 25: European ADHD study delivers positive results
European ADHD study delivers positive results E X PA N D I N G O U R P L AT F O R M B E Y O N D A U T I S M · F I R S T S T E P T O WA R D S B L I N K L A B D x 2 · W O R L D F I R S T rsonal use only 82% SENSITIVITY 83% SPECIFICITY 208 CHILDREN, AGED 6–17 Foundation for BlinkLab Dx2 One of the larg
Slide 26: Our expanding clinical study portfolio
Our expanding clinical study portfolio N I N E E X P L O R AT O R Y P R O G R A M S · F O U R R E A D O U T S I N C Y 2 0 2 6 , F I V E I N C Y 2 0 2 7 Early Clinical Regulatory Pilot Study Pivotal Study FDA FDA Commercial rsonal use only Work1 Preparation2 Program Program Submission Clearance Launc
Slide 27: A deep, global and now granted patent estate
A deep, global and now granted patent estate F O U R P A T E N T F A MI L I E S · 3 0 F I L I N G S · S E V E N J U R I S D I C T I O N S · F I R S T U S P A T E N T G R A N T E D J U N E 2 0 2 6 4 30 21 7 CY2041+ rsonal use only PATENT FAMILIES FILINGS WORLDWIDE LIVE APPLICATIONS JURISDICTIONS PROT
Slide 28: For more info, please contact
For more info, please contact: rsonal use only Brian Leedman Henk-Jan Boele, MD, PhD Non-Executive Chairman Co-founder and MD/CEO brian@blinklab.org henkjan@blinklab.org M: +61 (0) 412 281 780 M: +31 (0) 611 132 247 info@blinklab.org BlinkLab Limited (ASX:BB1) @BlinkLab Ltd @BlinkLab2193 @BlinkLab.A